These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2132205)

  • 21. Metabolic effects of dietary fructose in diabetic subjects.
    Bantle JP; Swanson JE; Thomas W; Laine DC
    Diabetes Care; 1992 Nov; 15(11):1468-76. PubMed ID: 1468273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
    Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
    Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Relationship between amitriptyline metabolism and polymorphic debrisoquine hydroxylation in native Chinese volunteers].
    Zhang XH; Yu P; Gu NF; Yin JL; Jiang WD
    Yao Xue Xue Bao; 1993; 28(2):85-91. PubMed ID: 8328289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotyped as extensive metabolizers.
    Cerqueira PM; Mateus FH; Cesarino EJ; Bonato PS; Lanchote VL
    J Chromatogr B Biomed Sci Appl; 2000 Dec; 749(2):153-61. PubMed ID: 11145052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances.
    Gawrońska-Szklarz B; Górnik W; Pawlik A; Kunicki P; Wójcicki J; Sitkiewicz D; Sych Z
    Eur J Clin Pharmacol; 1997; 51(6):431-5. PubMed ID: 9112055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of stereoselectivity and genetic polymorphism of the debrisoquine hydroxylation in man via analysis of urinary debrisoquine and 4-hydroxydebrisoquine by capillary electrophoresis.
    Lanz M; Theurillat R; Thormann W
    Electrophoresis; 1997 Sep; 18(10):1875-81. PubMed ID: 9372283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
    Sanz EJ; Bertilsson L
    Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diurnal effects on debrisoquine hydroxylation phenotyping.
    Lee EJ
    Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphic hydroxylation of Debrisoquine in man.
    Mahgoub A; Idle JR; Dring LG; Lancaster R; Smith RL
    Lancet; 1977 Sep; 2(8038):584-6. PubMed ID: 71400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
    Dalén P; Dahl M; Andersson K; Bertilsson L
    Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.
    Pollock BG; Perel JM; Altieri LP; Kirshner M; Fasiczka AL; Houck PR; Reynolds CF
    Psychopharmacol Bull; 1992; 28(2):163-8. PubMed ID: 1513919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
    Arvela P; Kirjarinta M; Kirjarinta M; Kärki N; Pelkonen O
    Br J Clin Pharmacol; 1988 Nov; 26(5):601-3. PubMed ID: 3207564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans.
    Dahl ML; Ekqvist B; Widén J; Bertilsson L
    Acta Psychiatr Scand; 1991 Jul; 84(1):99-102. PubMed ID: 1927573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.
    Eichelbaum M; Bertilsson L; Küpfer A; Steiner E; Meese CO
    Br J Clin Pharmacol; 1988 Apr; 25(4):505-8. PubMed ID: 3382592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results.
    Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM
    J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
    Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
    Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphic 4-hydroxylation of debrisoquine in a Turkish population.
    Sardas S; Pontin J; Idle JR
    Pharmacogenetics; 1991 Nov; 1(2):123-4. PubMed ID: 1844871
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.